Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19

Benedikt Strunz(Karolinska University Hospital), Christopher Maucourant(Karolinska University Hospital), Adi Mehta(Oslo University Hospital), Hui Wan(Karolinska Institutet), Likun Du(Karolinska Institutet), Dan Sun(Karolinska University Hospital), Puran Chen(Karolinska University Hospital), Anna Nordlander(Karolinska University Hospital), Yu Gao(Karolinska University Hospital), Martin Cornillet(Karolinska University Hospital), Jonna Bister(Karolinska University Hospital), Egle Kvedaraite(Karolinska University Hospital), Wanda Christ(Karolinska University Hospital), Jonas Klingström(Karolinska University Hospital), Daniel Geanon(Karolinska University Hospital), Åsa Parke(Karolinska University Hospital), Anna Ekwall-Larson(Karolinska Institutet), Laura Rivino(National University of Singapore), Paul A. MacAry(National University of Singapore), Soo Aleman(Karolinska University Hospital), Marcus Buggert(Karolinska University Hospital), Hans‐Gustaf Ljunggren(Karolinska University Hospital), Qiang Pan‐Hammarström(Karolinska Institutet), Fridtjof Lund‐Johansen(Oslo University Hospital), Kristoffer Strålin(Karolinska University Hospital), Niklas K. Björkström(Karolinska University Hospital), the Karolinska KI/K COVID-19 Study Group, Anders Sönnerborg, Lena Dillner, Hedvig Glans, Pontus Nauclér, Olav Rooyackers(Oslo University Hospital), Johan Mårtensson, Lars I. Eriksson, Björn P. Persson, Jonathan Grip, Christian Unge, Therese Djärv, Dorota Religa, John Tyler Sandberg, Helena Bergsten, Susanna Brighenti, Marta Butrym, Benedict J. Chambers, Angélica Cuapio, Isabel Diaz Lozano, Majda Dzidic, Johanna Emgård, Malin Flodström‐Tullberg, Jean‐Baptiste Gorin, Alvaro Haroun-Izquierdo(National University of Singapore), Laura Hertwig, Sadaf Kalsum, Efthymia Kokkinou, Nicole Marquardt, Magda Lourda, Kimia T. Maleki, Karl‐Johan Malmberg, Jakob Michaëlsson, Jenny Mjösberg, Kirsten Moll, Jagadeeswara Rao Muvva(Karolinska Institutet), Anna Norrby‐Teglund, Laura M. Palma Medina, Tiphaine Parrot, Lena Radler, Emma Ringqvist, Johan K. Sandberg, Takuya Sekine, Tea Soini, Mattias Svensson, Janne Tynell, Andreas von Kries, David Wullimann, André Perez‐Potti, Olga Rivera‐Ballesteros, Renata Varnaitė, Mira Akber, Lena Berglin, Demi Brownlie, Marco Giulio Loreti, Ebba Sohlberg, Tobias Kammann, Elisabet Welin Henriksson, Quirin Hammer
The Journal of Infectious Diseases
February 29, 2024
Cited by 6Open Access
Full Text

Abstract

BACKGROUND: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe disease with increased morbidity and mortality among certain risk groups. The presence of autoantibodies against type I interferons (aIFN-Abs) is one mechanism that contributes to severe coronavirus disease 2019 (COVID-19). METHODS: This study aimed to investigate the presence of aIFN-Abs in relation to the soluble proteome, circulating immune cell numbers, and cellular phenotypes, as well as development of adaptive immunity. RESULTS: aIFN-Abs were more prevalent in critical compared to severe COVID-19 but largely absent in the other viral and bacterial infections studied here. The antibody and T-cell response to SARS-CoV-2 remained largely unaffected by the presence aIFN-Abs. Similarly, the inflammatory response in COVID-19 was comparable in individuals with and without aIFN-Abs. Instead, presence of aIFN-Abs had an impact on cellular immune system composition and skewing of cellular immune pathways. CONCLUSIONS: Our data suggest that aIFN-Abs do not significantly influence development of adaptive immunity but covary with alterations in immune cell numbers.


Related Papers

No related papers found

Powered by citation graph analysis